Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Local immunotherapy for the treatment of cancer: scientific advances and clinical potential.

Journal for immunotherapy of cancer·2026

Same author

Immunotherapy Significantly Improves Merkel Cell Carcinoma-Specific Survival: A Single-Cohort Propensity Score-Matched Analysis.

medRxiv : the preprint server for health sciences·2026

Same author

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

BMJ oncology·2026

Same author

Healthcare Utilization Disparities Among Older Adults With and Without Cognitive Impairment: Health and Retirement Study Findings.

Journal of cross-cultural gerontology·2026

Same author

Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors.

Computational and structural biotechnology journal·2026

Same author

Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses.

Cancer immunology research·2026

Search research articles

Related Experiment Video

Updated: Aug 14, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Therapy with oncolytic viruses: progress and challenges.

Sophia Z Shalhout^1,2, David M Miller^1,2,3, Kevin S Emerick^2,4

¹Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Nature Reviews. Clinical Oncology

|January 11, 2023

Summary

This summary is machine-generated.

Oncolytic viruses (OVs) offer targeted cancer therapy with immune-boosting properties. This review details clinical experience with talimogene laherparepvec (T-VEC) and other OVs, guiding optimized use and overcoming development hurdles.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Experiment Videos

Last Updated: Aug 14, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Area of Science:

Oncolytic virotherapy
Cancer immunotherapy
Viral oncology

Background:

Oncolytic viruses (OVs) are a promising cancer therapeutic class with selective tumor cell replication and immune-stimulating effects.
Talimogene laherparepvec (T-VEC) is the only widely approved OV therapy, primarily for recurrent melanoma.
Despite progress, a deeper understanding of OV biology and pharmacology is crucial for maximizing their therapeutic potential.

Purpose of the Study:

To review current data on oncolytic viruses (OVs) for cancer treatment.
To provide guidance on optimizing the clinical use of OVs, focusing on talimogene laherparepvec (T-VEC).
To discuss novel OVs in clinical development and challenges in OV advancement.

Main Methods:

Literature review of clinical experience with talimogene laherparepvec (T-VEC).
Summary of data from clinical trials involving various oncolytic viruses (OVs).
Analysis of preclinical, clinical, and regulatory challenges impacting OV development.

Main Results:

Talimogene laherparepvec (T-VEC) has established clinical use for melanoma.
Data on T-VEC clinical experience is expanding, alongside trials of other OVs in diverse cancers.
Several novel OVs are in clinical development as monotherapies or combinations.

Conclusions:

Oncolytic viruses (OVs) represent a valuable therapeutic strategy in oncology.
Optimizing OV use requires a comprehensive understanding of their biology and clinical data.
Addressing existing hurdles is key to unlocking the full potential of oncolytic virotherapy.